Regeneron Pharmaceuticals Logo
US75886F1075
881535
REGN

Regeneron Pharmaceuticals

Loading quotes...

Forecast

The analysts' average price target is €821.84 (-6.33%). The median is €794.95 (-9.40%).

Buy
  34
Hold
  15
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Regeneron exceeds Q3 expectations significantly and hits 52-week high

    Regeneron reports Q3 revenue up 36% to $5.1 billion and adjusted earnings per share of $20.07 versus $16.24 expected. Collaboration revenue with Sanofi, mainly from Dupixent, rose 68% to $2.72 billion. Strong contributions also came from Libtayo and the higher-dose Eylea, which boosted revenues by $550 million and $699 million respectively; the stock rises about 8% in premarket trading. » More on deraktionaer.de


  • Regeneron highlights EYLEA HD momentum, Dupixent growth and upcoming pipeline catalysts

    Regeneron reported double-digit revenue and earnings growth with EYLEA HD comprising ~60% of EYLEA franchise sales and expected low- to mid-teens sequential demand growth in Q3 and Q4 despite biosimilar pressure. Dupixent is annualizing at about $24 billion and Libtayo grew over 30% year-over-year, strengthening position in U.S. lung cancer. Management flagged near-term catalysts including an FDA decision for cemdisiran in generalized myasthenia gravis in November, PNH data in Q4, Phase III and Phase II readouts in Factor XI and MASH programs, and melanoma data later this year. The company repurchased roughly $2 billion of stock in H1 and continues to prioritize pipeline funding, business development, dividends and buybacks. » More on finance.yahoo.com


  • Regeneron continues to rely on Dupixent for growth and advances pipeline and production expansion

    Regeneron sees Dupixent as its main growth driver and expects about USD 22 billion for its US business in 2026, assuming a market penetration of roughly 15–20% in atopic dermatitis. EYLEA HD is gaining market share in the anti‑VEGF segment, while biosimilars are likely to intensify competition in 2026/2027. Key pipeline milestones include cemdisiran with an FDA decision for generalized myasthenia gravis in November 2026 and PNH and GA data at the end of 2026; several DUPIXENT follow‑on programs are planned. Regeneron is expanding production capacity in northern New York and is prioritizing capital allocation for internal research, selective acquisitions and share buybacks. » More on de.investing.com


  • American Century sells Regeneron, cites limited upside from sluggish commercialization

    American Century Investments' Focused Dynamic Growth Fund disclosed it sold its Regeneron position, saying longstanding confidence in the company's research platform has been undermined by weak commercialization of its macular degeneration treatment and limited appreciation potential. The fund redeployed proceeds into names it views as having better upside, amid a quarter where growth and AI stocks led performance while healthcare lagged. Hedge fund ownership of Regeneron also declined slightly quarter‑over‑quarter. » More on finance.yahoo.com


  • Regeneron announces broad-based growth and deep pipeline at Wells-Fargo conference

    At the Wells-Fargo Healthcare Conference, Regeneron presented a strategy for broader growth, stronger operational execution and an expanded product pipeline. In Q2 2026 the company recorded double-digit revenue and earnings gains, driven by record sales of EYLEA HD, DUPIXENT and LIBTAYO; DUPIXENT reached an annualized run rate of USD 24 billion. Regeneron identified several near-term catalysts, including the PDUFA date for Cemdisiran in generalized myasthenia gravis and a regulatory filing for an EYLEA-HD prefilled syringe by year-end. Management emphasized the long-term advantage of its linked genetics and proteomics database for AI-powered drug discovery and signaled openness to selective business collaborations with Sanofi at disciplined valuations. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Regeneron Pharmaceuticals has already paid €2.43 in dividends. The last payout was in August.

Financials

In the last quarter, Regeneron Pharmaceuticals had revenue of €4.52bn and net profit of €1.72bn
(EUR) September 2026
YoY
Revenue 4.52bn 41.18%
Gross profit 4.01bn 45.57%
Net profit 1.72bn 38.28%
EBITDA 2.13bn 30.40%

Fundamentals

Metric Value
Market capitalization
€89.78bn
Number of shares
103.43m
52-week high/low
€901.00 - €537.40
Dividend yield
0.37%
Dividends TTM
€3.18
Next dividend
€0.85
Beta
0.24
P/E ratio
20.35
PEG ratio
2.52
P/B ratio
2.90
P/S ratio
5.85

Company profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Name
Regeneron Pharmaceuticals
CEO
Leonard S. Schleifer
Headquarters Tarrytown, ny
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
12/09/2017
Employees 15,410

Ticker symbols

Exchange Symbol
NASDAQ
REGN
London Stock Exchange
0R2M.L
Frankfurt
RGO.F
DĂĽsseldorf
RGO.DU
Hamburg
RGO.HM
Milan
1REGN.MI
London
0R2M.L
SIX
RGO.SW
MĂĽnchen
RGO.MU
Wien
REGN.VI
XETRA
RGO.DE
🍪

Parqet  uses cookies. Learn more